



| | | |
|--|---------------------------------|-------------------------------------|
| Substitute for Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) | ATTY DOCKET NO. 9516-207-999 | APPLICATION NO. 10/534,325 |
| | APPLICANT: Zeldis | |
| | FILING DATE: May 5, 2005 | ART UNIT: 1614 CONF. NO.: 9771 |

U.S. PATENT DOCUMENTS

| EXAMINER'S INITIALS* | DOCUMENT NUMBER | DATE MM/DD/YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
|----------------------|-----------------|-----------------|---|---|
| | | | | |

FOREIGN PATENT DOCUMENTS

| EXAMINER'S INITIALS* | Country Code, Number, Kind of Code (if known) | DATE MM/DD/YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | TRANSLATION | |
|----------------------|---|-----------------|---|---|-------------|----|
| | | | | | YES | NO |

NON PATENT LITERATURE DOCUMENTS (include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, etc.), date, page(s), volume, publisher, city and/or country where published., etc.)

| EXAMINER'S INITIALS* | | |
|----------------------|-----|--|
| SG | C66 | DREDGE et al., 2003, "Angiogenesis inhibitors in cancer therapy," Curr. Opin. Investig. Drugs 4(6):667-673 |
| SG | C67 | DREDGE et al., 2002, "Immunological effects of thalidomide and its chemical and functional analogs," Crit. Rev. Immunol. 22(5-6):425-437 |
| SG | C68 | DREDGE et al., 2002, "Recent developments in antiangiogenic therapy," Expert Opin. Biol. Ther. 2(8):953-966 |
| SG | C69 | GEE et al., 2003, "Selective cytokine inhibitory drugs with enhanced antiangiogenic activity control tumor growth through vascular inhibition," Cancer Res. 63(23):8073-8078 |
| SG | C70 | MARRIOTT et al., 2001, "Immunotherapeutic and antitumour potential of thalidomide analogues," Expert Opin. Biol. Ther. 1(4):1-8 |
| SG | C71 | MARRIOTT et al., 2002, "Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during co-stimulation of both CD4(+) and CD8(+) T cells," Clin. Exp. Immunol. 130(1):75-84 |
| SG | C72 | MOLOSTVOV et al., 2004, "The effects of selective cytokine inhibitory drugs (CC-10004 and CC-1088) on VEGF and IL-6 expression and apoptosis in myeloma and endothelial cell co-cultures," Br. J. Haematol. 124(3):366-375 |
| SG | C73 | ZELDIS et al., 2003, "Potential new therapeutics for Waldenstrom's macroglobulinemia," Semin. Oncol. 30(2):275-281 |

| | |
|---|-----------------------------------|
| EXAMINER /Shirley Gembeh/ | DATE CONSIDERED 07/21/2006 |
| *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | |

| | | |
|--|---------------------------------|---|
| Substitute for Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) | ATTY DOCKET NO. 9516-207-999 | APPLICATION NO. 10/534,325 |
| | APPLICANT: Zeldis | |
| | FILING DATE: May 5, 2005 | ART UNIT: CONF. NO.: 1614 9771 |

U.S. PATENT DOCUMENTS

| EXAMINER'S INITIALS* | DOCUMENT NUMBER | DATE MM/DD/YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
|----------------------|-----------------|-----------------|---|---|
| | | | | |

FOREIGN PATENT DOCUMENTS

| EXAMINER'S INITIALS* | Country Code, Number, Kind of Code (if known) | DATE MM/DD/YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | TRANSLATION | |
|----------------------|---|-----------------|---|---|-------------|----|
| | | | | | YES | NO |

NON PATENT LITERATURE DOCUMENTS (include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, etc.), date, page(s), volume, publisher, city and/or country where published., etc.)

| EXAMINER'S INITIALS* | | |
|----------------------|-----|---|
| SG | C62 | DATABASE NLDB XP002371400 retrieved from STN. Database accession no. 2002:87776, & BIOWORLD Today, Vol. 13, No. 68. April 10, 2002. |
| SG | C63 | DATABASE PHIN "Celgene moving beyond Thalidomid" XP002371401 retrieved from STN. Database accession no. 2001:12958, & SCRIP (Newsletter), No. 2657 p. 12. July 4, 2001. |
| SG | C64 | LI et al., "Tumor angiogenesis: Molecular pathology, therapeutic targeting, and imaging," 2000, Academic Radiology, 7(10):800-811. |
| SG | C65 | OLIVER et al., "Thalidomide analogue CC1069 inhibits development of rat adjuvant arthritis," 1999, Clinical and Experimental Immunology, 118(2):315-321. |

| | |
|---|-------------------------------|
| EXAMINER /Shirley Gembah/ | DATE CONSIDERED 07/21/2006 |
| *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | |

LIST OF REFERENCES CITED BY APPLICANT
(Use several sheets if necessary)

ATTY. DOCKET NO.

9516-207-999

APPLICATION NO.

10/534,325

APPLICANT

Zeldis

FILING DATE

May 5, 2005

GROUP

To Be Assigned

U.S. PATENT DOCUMENTS

| *EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE |
|----------------------|-----|-----------------|----------|-------------------|-------|----------|-------------------------------|
| SG | A01 | 60/499,723 | | Markian | | | 9/4/03 |
| | A02 | 60/454,149 | | Man et al. | | | 3/12/03 |
| | A03 | 60/452,460 | | Muller et al. | | | 3/5/03 |
| | A04 | 60/438,450 | | Muller et al. | | | 1/7/03 |
| | A05 | 60/438,448 | | Muller et al. | | | 1/7/03 |
| | A06 | 60/372,348 | | Hariri et al. | | | 4/12/02 |
| | A07 | 10/748,085 | | Zhang et al. | | | 12/29/03 |
| | A08 | 09/545,654 | | D'Amato | | | 4/10/00 |
| | A09 | 09/287,377 | | D'Amato | | | 4/7/99 |
| | A10 | 2005/0014727 | 1/20/05 | Muller et al. | | | |
| | A11 | 2004/0266809 | 12/30/04 | Emanuel et al. | | | |
| | A12 | 2004/0259873 | 12/23/04 | Man et al. | | | |
| | A13 | 2004/0254214 | 12/16/04 | Man et al. | | | |
| | A14 | 2004/0167199 | 8/26/04 | Muller et al. | | | |
| | A15 | 2004/0127545 | 7/1/04 | Green et al. | | | |
| | A16 | 2004/0122052 | 6/24/04 | Muller et al. | | | |
| | A17 | 2004/0091455 | 5/13/04 | Zeldis | | | |
| | A18 | 2004/0087546 | 5/6/04 | Zeldis | | | |
| | A19 | 2004/0077686 | 4/22/04 | Dannenberg et al. | | | |
| | A20 | 2004/0077685 | 4/22/04 | Figg et al. | | | |
| | A21 | 2004/0029832 | 2/12/04 | Zeldis | | | |
| | A22 | 2003/0235909 | 12/25/03 | Hariri et al. | | | |
| | A23 | 2003/0191098 | 10/9/03 | D'Amato | | | |
| | A24 | 2003/0187052 | 10/2/03 | Schafer et al. | | | |
| | A25 | 2003/0187024 | 10/2/03 | D'Amato | | | |
| | A26 | 2003/0185826 | 10/2/03 | Tobinick | | | |
| | A27 | 2003/0181428 | 9/25/03 | Green et al. | | | |
| | A28 | 2003/0144325 | 7/31/03 | Muller et al. | | | |
| | A29 | 2003/0139451 | 7/24/03 | Shah et al. | | | |
| | A30 | 2003/0113318 | 6/19/03 | Tobinick | | | |
| | A31 | 2003/0069428 | 4/10/03 | Muller et al. | | | |
| | A32 | 2003/0049256 | 3/13/03 | Tobinick | | | |
| | A33 | 2003/0028028 | 2/6/03 | Man et al. | | | |
| | A34 | 2003/0013739 | 1/16/03 | Masferrer et al. | | | |
| | A35 | 2003/0007972 | 1/9/03 | Tobinick | | | |
| SG | A36 | 2002/0183360 | 12/5/02 | Muller et al. | | | |

| | | | | | | | |
|----|-----|--------------|----------|----------------------|--|--|--|
| SG | A37 | 2002/0173658 | 11/21/02 | Muller et al. | | | |
| | A38 | 2002/0161023 | 10/31/02 | D'Amato | | | |
| | A39 | 2002/0131955 | 9/19/02 | Tobinick | | | |
| | A40 | 2002/0131954 | 9/19/02 | Tobinick | | | |
| | A41 | 2002/0128228 | 9/12/02 | Hwu | | | |
| | A42 | 2002/0061923 | 5/23/02 | D'Amato | | | |
| | A43 | 2002/0054899 | 5/9/02 | Zeldis | | | |
| | A44 | 2002/0052398 | 5/2/02 | D'Amato | | | |
| | A45 | 2002/0045643 | 4/18/02 | Muller et al. | | | |
| | A46 | 2002/0035090 | 3/21/02 | Zeldis et al. | | | |
| | A47 | 2001/0056114 | 12/27/01 | D'Amato | | | |
| | A48 | 2001/0026801 | 10/4/01 | Tobinick | | | |
| | A49 | 2001/0018445 | 8/30/01 | Huang et al. | | | |
| | A50 | 2001/0016195 | 8/23/01 | Tobinick | | | |
| | A51 | 2001/0004456 | 6/21/01 | Tobinick | | | |
| | A52 | 6,699,899 | 3/2/04 | Man et al. ✓ | | | |
| | A53 | 6,667,316 | 12/23/03 | Man et al. | | | |
| | A54 | 6,623,736 | 9/23/03 | Tobinick | | | |
| | A55 | 6,537,549 | 3/25/03 | Tobinick | | | |
| | A56 | 6,518,298 | 2/11/03 | Green et al. | | | |
| | A57 | 6,518,281 | 2/11/03 | Muller et al. | | | |
| | A58 | 6,479,554 | 11/12/02 | Muller et al. | | | |
| | A59 | 6,471,961 | 10/29/02 | Tobinick | | | |
| | A60 | 6,469,045 | 10/22/02 | D'Amato | | | |
| | A61 | 6,458,810 | 10/1/02 | Muller et al. | | | |
| | A62 | 6,429,221 | 8/6/02 | Muller et al. | | | |
| | A63 | 6,428,787 | 8/6/02 | Tobinick | | | |
| | A64 | 6,423,321 | 7/23/02 | Tobinick | | | |
| | A65 | 6,420,414 | 7/16/02 | D'Amato | | | |
| | A66 | 6,419,944 | 7/16/02 | Tobinick | | | |
| | A67 | 6,419,934 | 7/16/02 | Tobinick | | | |
| | A68 | 6,403,613 | 6/11/02 | Man et al. | | | |
| | A69 | 6,395,754 | 5/28/02 | Muller et al. | | | |
| | A70 | 6,380,239 | 4/30/02 | Muller et al. | | | |
| | A71 | 6,379,666 | 4/30/02 | Tobinick | | | |
| | A72 | 6,326,388 | 12/4/01 | Man et al. | | | |
| | A73 | 6,284,780 | 9/4/01 | Muller et al. | | | |
| | A74 | 6,262,101 | 7/17/01 | Muller et al. | | | |
| | A75 | 6,235,756 | 5/22/01 | D'Amato | | | |
| | A76 | 6,214,857 | 4/10/01 | Muller et al. | | | |
| | A77 | 6,200,987 | 3/13/01 | Muller | | | |
| | A78 | 6,180,644 | 1/30/01 | Muller et al. | | | |
| | A79 | 6,177,077 | 1/23/01 | Tobinick | | | |
| ↓ | A80 | 6,140,346 | 10/31/00 | Andrulis, Jr. et al. | | | |
| SG | A81 | 6,130,226 | 10/10/00 | Muller et al. | | | |

| | | | | | | | |
|----|------|-----------|----------|----------------------|--|--|--|
| SG | A82 | 6,114,355 | 9/5/00 | D' Amato | | | |
| | A83 | 6,075,041 | 6/13/00 | Muller | | | |
| | A84 | 6,046,221 | 4/4/00 | Muller et al. | | | |
| | A85 | 6,020,358 | 2/1/00 | Muller et al. | | | |
| | A86 | 6,015,557 | 1/18/00 | Tobinick et al. | | | |
| | A87 | 6,011,050 | 1/4/00 | Muller et al. | | | |
| | A88 | 5,968,945 | 10/19/99 | Muller et al. | | | |
| | A89 | 5,955,476 | 9/21/99 | Muller et al. | | | |
| | A90 | 5,929,117 | 7/27/99 | Muller et al. | | | |
| | A91 | 5,877,200 | 3/2/99 | Muller | | | |
| | A92 | 5,801,195 | 9/1/98 | Muller et al. | | | |
| | A93 | 5,736,570 | 4/7/98 | Muller et al.. | | | |
| | A94 | 5,733,566 | 3/31/98 | Lewis | | | |
| | A95 | 5,731,325 | 3/24/98 | Andrulis, Jr. et al. | | | |
| | A96 | 5,728,845 | 3/17/98 | Muller et al. | | | |
| | A97 | 5,728,844 | 3/17/98 | Muller et al. | | | |
| | A98 | 5,712,291 | 1/27/98 | D' Amato | | | |
| | A99 | 5,703,098 | 12/30/97 | Muller et al. | | | |
| | A100 | 5,674,533 | 10/7/97 | Santus et al. | | | |
| | A101 | 5,698,579 | 12/16/97 | Muller | | | |
| | A102 | 5,658,940 | 8/19/97 | Muller et al. | | | |
| | A103 | 5,639,476 | 6/17/97 | Oshlack et al. | | | |
| | A104 | 5,605,914 | 2/25/97 | Muller | | | |
| | A105 | 5,591,767 | 1/7/97 | Mohr et al. | | | |
| | A106 | 5,580,755 | 12/3/96 | Souza | | | |
| | A107 | 5,528,823 | 6/25/96 | Rudy, Jr. et al. | | | |
| | A108 | 5,463,063 | 10/31/95 | Muller | | | |
| | A109 | 5,393,870 | 2/28/95 | Deeley et al. | | | |
| | A110 | 5,391,485 | 2/21/95 | Deeley et al. | | | |
| | A111 | 5,385,901 | 1/31/95 | Kaplan et al. | | | |
| | A112 | 5,354,556 | 10/11/94 | Sparks et al. | | | |
| | A113 | 5,229,496 | 7/20/93 | Deeley et al. | | | |
| | A114 | 5,134,127 | 7/28/92 | Stella et al. | | | |
| | A115 | 5,120,548 | 6/9/92 | McClelland et al. | | | |
| | A116 | 5,073,543 | 12/17/91 | Marshall et al. | | | |
| | A117 | 5,059,595 | 10/22/91 | Le Grazie | | | |
| | A118 | 4,999,291 | 3/12/91 | Souza | | | |
| | A119 | 4,810,643 | 3/7/89 | Souza | | | |
| | A120 | 4,008,719 | 2/22/77 | Theeuwes et al. | | | |
| | A121 | 3,916,899 | 11/4/75 | Theeuwes et al: | | | |
| | A122 | 3,845,770 | 11/5/74 | Theeuwes et al. | | | |
| | A123 | 3,598,123 | 8/10/71 | Zaffaroni et al. | | | |
| SG | A124 | 3,536,809 | 10/27/70 | Applezweig | | | |

| FOREIGN PATENT DOCUMENTS | | | | | | | | |
|--------------------------|-----|-----------------|----------|---------|-------|----------|-------------|----|
| | | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUBCLASS | TRANSLATION | |
| | | | | | | | YES | NO |
| SG | B01 | WO 03/086373 | 10/23/03 | PCT | | | | |
| | B02 | WO 03/080049 | 10/2/03 | PCT | | | | |
| | B03 | WO 03/080048 | 10/2/03 | PCT | | | | |
| | B04 | WO 02/064083 | 8/22/02 | PCT | | | | |
| | B05 | WO 01/70275 | 9/27/01 | PCT | | | | |
| | B06 | WO 01/45702 | 6/28/01 | PCT | | | | |
| | B07 | WO 01/34606 | 5/17/01 | PCT | | | | |
| | B08 | WO 01/087307 | 11/22/01 | PCT | | | | |
| | B09 | WO 99/06041 | 2/11/99 | PCT | | | | |
| | B10 | WO 97/23457 | 7/3/97 | PCT | | | | |
| | B11 | WO 97/08143 | 3/6/97 | PCT | | | | |
| SG | B12 | WO 95/01348 | 1/12/95 | PCT | | | | |

| OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.) | | | | | | | | |
|---|-----|--|--|--|--|--|--|--|
| SG | C01 | Alexanian et al., 2004, "VTD (Velcade, thalidomide, dexamethasone) as primary therapy for newly-diagnosed multiple myeloma," Am. Soc. Hematol. 46 th Ann. Meeting Dec. 4-7, 2004, San Diego, CA Abstract #210 | | | | | | |
| | C02 | Anderson, 2000, "Thalidomide: Therapeutic potential in hematologic malignancies," Seminars in Hematology 37(1 Supp 3): 1-4 | | | | | | |
| | C03 | Attal et al., 2004, "Maintenance treatment with thalidomide after autologous transplantation for myeloma: First analysis of a prospective randomized study of the Intergroupe Francophone du Myelome (IFM 99 02)," Am. Soc. Hematol. 46 th Ann. Meeting Dec. 4-7, 2004, San Diego, CA Abstract #535 | | | | | | |
| | C04 | Bach, 1963, "Thalidomide in Cancer Chemotherapy," <i>The Lancet</i> , June 8, No. 1271, pg. 71 | | | | | | |
| | C05 | Bach, 1963, "Studies on the Possible Anti-Neoplastic Effect of Thalidomide," <i>Acta Pathologica Et Microbiologica Scandinavica</i> 59:491-499 | | | | | | |
| | C06 | Bernardeschi et al., 2003, "Low dose thalidomide plus monthly high-dose oral dexamethasone (thali-dexa): Results, prognostic factors and side effects in eight patients previously treated with multiple myeloma," <i>J. Exp. Clin. Cancer Res.</i> 22(Supp 4):129-133 | | | | | | |
| | C07 | Cartensen, 1995, <i>Drug Stability: Principles & Practice</i> , 2 nd ed., New York pp. 379-380 | | | | | | |
| | C08 | Chaundhry, 1966, "Effect of Prednisolone and Thalidomide on Induced Submandibular Gland Tumors in Hamster," <i>Cancer Research</i> 26(part 1):1884-86 | | | | | | |
| | C09 | Corral et al., 1999, "Immunomodulation by thalidomide and thalidomide analogues," <i>Ann. Rheum. Dis.</i> 58(Suppl 1):1107-1113 | | | | | | |
| | C10 | Craig et al., 1967, "Potential anticancer agents. III. 2-phthalimidoaldehydes and derivatives," <i>Potential Anticancer Agents</i> III 10:1071-1073 | | | | | | |
| | C11 | D'Amato et al., 2001, "Mechanism of action of thalidomide and 3-aminothalidomide in multiple myeloma," <i>Semin. Oncol.</i> 28:597-601 | | | | | | |
| | C12 | D'Amato et al., 1994, "Thalidomide is an Inhibitor of Angiogenesis", <i>Proc. Natl. Acad. Sci.</i> 91:4082-4085 | | | | | | |
| | C13 | Davies et al., 2001, "Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma," <i>Blood</i> 98(1):210-216 | | | | | | |
| | C14 | De et al., 1976, "Hansch analysis for some antineoplastic glutarimides," <i>J. Indian Chem. Soc.</i> I.III: 825-826 | | | | | | |
| | C15 | De et al., 1976, "Possible antineoplastic agents. III. Synthesis of 6-alkyl-2-[4'-methoxyphthalimido] and 6-alkyl-3-[3'-4'-dimethoxyphenyl] glutarimides," <i>J. Indian Chem. Soc.</i> I.III:1122-1125 | | | | | | |
| | C16 | Dimopoulos et al., 2004, "Primary treatment with pulsed melphalan, dexamethasone, thalidomide (MDT) for symptomatic patients with multiple myeloma ≥75 years of age," Am. Soc. Hematol. 46 th Ann. Meeting Dec. 4-7, 2004, San Diego, CA Abstract #1482 | | | | | | |
| | C17 | DiPaolo, June 26, 1964, "Thalidomide: Effects on Ehrlich Ascites Tumor Cells <i>in vitro</i> " <i>Science</i> 144:1583 | | | | | | |
| | C18 | DiPaolo, 1963, "Effect of Thalidomide on a Variety of Transplantable Tumors," <i>Cancer Chemotherapy Reports</i> No. 29, p. 99-102 | | | | | | |
| SG | C19 | DiPaolo, 1963, "In vitro Test Systems for Cancer Chemotherapy, II. Correlation of <i>in vitro</i> Inhibition of Dehydrogenase and Growth with <i>in vivo</i> Inhibition of Ehrlich Asciotes Tumor," <i>Proceedings of the Society for Experimental Biology & Medicine</i> 114:384-387 | | | | | | |

| | | |
|----|-----|---|
| SG | C20 | Dredge et al., 2002, "Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects," Br. J. Cancer 87(10):1166-1172 |
| | C21 | Eisen et al., 2000, "Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer," Br. J. Cancer 82(4):812-817 |
| | C22 | Emens et al., 2001, "Chemotherapy: friend or foe to cancer vaccines?" Curr. Opin. Mol. Ther. 3(1):77-84 |
| | C23 | Fakhouri et al., 2004, "Thalidomide in patients with multiple myeloma and renal failure," Br. J. Haematol. 125:90-102 |
| | C24 | Fenk et al., 2005, "Single-agent thalidomide for treatment of first relapse following high-dose chemotherapy in patients with multiple myeloma," Leukemia 19(1):156-159 |
| | C25 | Folkman et al., 1983, "Angiogenesis inhibition and tumor regression caused by heparin or a heparin fragment in the presence of cortisone," Science 221(4612):719-725 |
| | C26 | Gershbein, 1991, "The thalidomide analog, EM 12, enhances 1,2-dimethylhydrazine-induction of rat colon adenocarcinomas," Cancer Letters 60: 129-133 |
| | C27 | Grabstald et al., 1965, "Clinical experiences with thalidomide in patients with cancer," Clinical Pharmacology and Therapeutics 6:298-302 |
| | C28 | Gupta et al., 2001, "Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications," Leukemia 15(12):1950-1961 |
| | C29 | Haslett et al., 2003, "Thalidomide and a thalidomide analogue drug costimulate virus-specific CD8+ T cells in vitro," J. Infect. Dis. 187(6):946-955 |
| | C30 | He, W., et al., 1993, Abstract of papers, 206th American Chemical Society, Chicago, IL; Med. Chem., paper 216 |
| | C31 | Hideshima et al., 2000, "Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy," Blood 96(9):2943-2950 |
| | C32 | Jonsson, 1972, "Chemical Structure and Teratogenic Properties," Acta Pharm., pp. 521-542. |
| | C33 | Lentzsch et al., 2003, "Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo," Leukemia 17(1):41-44 |
| | C34 | Lentzsch et al., 2002, "S-3-amino-phthalimido-glutarimide inhibits angiogenesis and growth of B-cell neoplasias in mice," Cancer Research 62:2300-2305 |
| | C35 | Mauad, 1963, "Clinical Improvements Obtained in Advanced Cancer Patients with Treatment with Thalidomide Associated with Hormones," Anais Paulistas de Medicina e Cirurgia, 86:13-40 |
| | C36 | Miyachi et al., 1997, "Novel biological response modifiers: phthalimides with tumor necrosis factor-alpha production-regulating activity," J. Med. Chem. 40:2858-2865 |
| | C37 | Muckter, 1966, "Thalidomide and Tumor," Antimicrobial Agents and Chemotherapy pp. 531-538 |
| | C38 | Muller et al., 1999, "Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production," Bioorg. Med. Chem. Lett. 9(11):1625-1630 |
| | C39 | Muller et al., 1998, "Thalidomide analogs and PDE4 inhibition," Bioorg. Med. Chem. Lett. 8(19):2669-2674 |
| | C40 | Muller et al., 1996, "Structural modifications of thalidomide produce analogs with enhanced tumor necrosis factor inhibitory activity," J. Med. Chem. 39(17):3238-3240 |
| | C41 | Offidani et al., 2003, "Thalidomide plus oral melphalan for advanced multiple myeloma: a phase II study," Haematologica 88(12):1432-1433 |
| | C42 | Olson et al., 1965, "Thalidomide (N-phthaloylglutaramide) in the treatment of advanced cancer," Clinical Pharmacology and Therapeutics 6(3):292-297 |
| | C43 | Palumbo et al., 2004, "A prospective randomized trial of oral melphalan prednisone, thalidomide (MPT) vs. oral melphalan, prednisone (MP): An interim analysis," Am. Soc. Hematol. 46 th Ann. Meeting Dec. 4-7, 2004, San Diego, CA Abstract #207 |
| | C44 | Penichet et al., 2001, "Antibody-cytokine fusion proteins for the therapy of cancer," J. Immunol. Methods 248(1-2):91-101 |
| | C45 | Physicians' Desk Ref. 2002, 56 th ed., pp. 1755-1760 |
| | C46 | Raje et al., 1999, "Thalidomide--a revival story," N. Engl. J. Med. 341(21):1606-1609 |
| | C47 | Rajkumar et al., 2004, "Thalidomide plus dexamethasone versus dexamethasone alone in newly diagnosed multiple myeloma (E1A00): Results of a phase III trial coordinated by the Eastern Cooperative Oncology Group," Am. Soc. Hematol. 46 th Ann. Meeting Dec. 4-7, 2004, San Diego, CA Abstract #205 |
| | C48 | Rajkumar et al., 2000, "Prognostic value of bone marrow angiogenesis in multiple myeloma," Clin. Cancer Res. 6(8):3111-3116 |
| | C49 | Raza et al., 2001, "Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes," Blood 98(4):958-965 |
| | C50 | Ribatti et al., 1999, "Bone marrow angiogenesis and mast cell density increase simultaneously with progression of human multiple myeloma," Br. J. Cancer 79(3-4):451-455 |
| | C51 | Roe et al., 1963, "Thalidomide and Neoplasia," Nature, December 7, 200:1016-17 |
| V | C52 | Shah et al., 1999, "Synthesis and enantiomeric separation of 2-phthalimidino-glutaric acid analogues: potent inhibitors of tumor metastasis," J. Med. Chem. 42:3014-3017 |
| SG | C53 | Shibata et al., 1995, "N-alkylphthalimides: structural requirement of thalidomide action on 12-O-tetradecanoylphorbol-13-acetate-induced tumor necrosis factor production by human leukemia HL-60 cells," Chem. |

| | | |
|----|-----|--|
| SG | | Pharm. Bull. 43(1):177-179 |
| | C54 | Shimazawa et al., 1999, "Antiangiogenic activity of tumor necrosis factor-alpha production regulators derived from thalidomide," Biol. Pharm. Bull. 22(2):224-226 |
| | C55 | Singhal et al., 1999, "Antitumor activity of thalidomide in refractory multiple myeloma," N. Engl. J. Med. 341(21):1565-1571 |
| | C56 | Steins et al., 2002, "Efficacy and safety of thalidomide in patients with acute myeloid leukemia," Blood 99(3):834-839 |
| | C57 | Stockdale, 1998, <i>Medicine</i> , Rubenstein and Federman, eds., Vol. 3, Ch. 12, Sections IV and X |
| | C58 | Sugiura et al., 1964, "Effect of thalidomide on transplantable mouse, rat, and hamster tumors," Gann. 55:57-60 |
| | C59 | Vacca et al., 1999, "Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma," Blood 93(9):3064-3073 |
| ↓ | C60 | Wohrer et al., 2004, "Effective treatment of primary plasma cell leukemia with thalidomide and dexamethasone - a case report," Hematol. J. 5:361-363 |
| SG | C61 | Wolff, ed., 1995, 1 Burger's Medicinal Chemistry and Drug Discovery, 5 th ed., 172-178, 949-982 |

| | | | |
|---|------------------|-----------------|------------|
| EXAMINER | /Shirley Gembeh/ | DATE CONSIDERED | 07/21/2006 |
| *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | | |